Wave Life Sciences, Inc. (WVE): Shareholders' Equity
$518.36M
As of 2025-12-31
$453.52M
As of 2026-06-30
+44.3%
5-year compound annual growth
+12.9%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $518.36M | +147.4% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $209.51M | +428.7% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $39.63M | n/m | 2026-02-26, Balance as of period end |
| 2022-12-31 | -$45.09M | n/m | 2025-03-04, Balance as of period end |
| 2021-12-31 | $32.50M | -60.7% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $82.78M | +29.9% | 2022-03-03, Balance as of period end |
| 2019-12-31 | $63.73M | -13.1% | 2021-03-04, Balance as of period end |
| 2018-12-31 | $73.35M | -47.5% | 2020-03-02, Balance as of period end |
| 2017-12-31 | $139.61M | +3.7% | 2020-03-02, Balance as of period end |
| 2016-12-31 | $134.60M | -12.3% | 2019-03-01, Balance as of period end |
| 2015-12-31 | $153.49M | n/m | 2018-03-12, Balance as of period end |
| 2014-12-31 | $2.03M | n/m | 2017-03-16, Balance as of period end |
| 2013-12-31 | -$7.76M | n/a | 2016-03-30, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $518.36M | +147.4% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $35.27M | +100.4% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $10.48M | +136.4% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $24.88M | +8.9% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | -$33.66M | n/m |
| Septerna, Inc. (SEPN) | 2025-12-31 | $381.93M | -9.1% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $614.71M | -9.0% |
| BGM Group Ltd. (BGM) | 2025-09-30 | $391.90M | +788.8% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | -$122.76M | n/m |
Compare WVE, XLO, BFRI, CPIX side by side · Screen every company in Pharmaceutical Preparations ↗